Journal of Alzheimer's disease reports最新文献

{"title":"Current use and perspectives of PET imaging in Alzheimer's disease: A Spanish national survey.","authors":"María Nieves Cabrera-Martín, Pablo Aguiar-Fernández, Valle Camacho-Martí, Edgar F Guillén-Valderrama, Julio Francisco Jiménez-Bonilla, José Antonio Lojo-Ramírez, Diego Alfonso López-Mora, Jordi A Matías-Guiu, Patricia Paredes-Rodríguez, Andrés Perissinotti, Javier Arbizu","doi":"10.1177/25424823261437129","DOIUrl":"https://doi.org/10.1177/25424823261437129","url":null,"abstract":"<p><strong>Background: </strong>Novel therapies for Alzheimer's disease are expected to increase the demand for biomarkers. PET will likely play a central role in patient selection and treatment monitoring, requiring adequate infrastructure and trained professionals.</p><p><strong>Objective: </strong>To assess the current status of Nuclear Medicine departments in Spain regarding organization, expertise, and available infrastructure.</p><p><strong>Methods: </strong>We conducted a nationwide survey among Nuclear Medicine departments in Spain.</p><p><strong>Results: </strong>Respondents averaged 19.8 years of professional experience; 62.0% had specific neuroimaging training and 76.0% reported high confidence in amyloid PET interpretation. Hospitals were mainly public (70.6%) and widely distributed geographically, and 73.0% reported having cognitive impairment units. Following the INVEAT plan, Spain currently has 147 PET scanners, although capacity varies: most centers operate one scanner and five reported having none. Amyloid PET is available in 77.0% of departments, with annual volumes ranging from fewer than 10 to more than 100 studies; 15.0% cannot perform amyloid PET due to regional limitations. Quantification tools are available in 41.3% of centers, although only 15.5% include quantitative metrics in reports, while 66.7% support the use of centiloid standardization. Nearly all respondents anticipate increased indications for amyloid PET (screening 83.7%; monitoring 68.5%) and support multidisciplinary collaboration (89.1% favor Neuroimaging Committees). About half report workforce needs, mainly nuclear medicine physicians (46.2%). Research activity in Alzheimer's disease is expected to increase (95.6%).</p><p><strong>Conclusions: </strong>Most departments recognize the key role of amyloid PET for anti-amyloid therapy implementation and anticipate increased demand, highlighting the need to expand availability, implement quantification tools, and strengthen multidisciplinary collaboration.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261437129"},"PeriodicalIF":2.8,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of statin interventions on cognitive function by Mendelian randomization study.","authors":"Yan He, Heng Yang, Ting Pan, Fang Wang, Xiaofeng Zeng, Jiagui Huang, Qin Yang","doi":"10.1177/25424823261440863","DOIUrl":"https://doi.org/10.1177/25424823261440863","url":null,"abstract":"<p><strong>Background: </strong>While statin use is linked to cognitive impairment, causal relationships with specific dementia subtypes remain unclear.</p><p><strong>Objective: </strong>To investigate causal effects of statin medication, genetically mimicked statin effects, and plasma lipids on various cognitive impairments using Mendelian randomization (MR).</p><p><strong>Methods: </strong>Utilizing summary genome-wide association studies data, we identified genetic variants associated with statin medication, cholesterol-dependent/independent statin effects, and dementia subtypes, such as Alzheimer's disease (AD), dementia in Alzheimer's disease (ADD), late-onset Alzheimer's disease, dementia with Lewy body (DLB), dementia with Lewy body in <i>APOE</i> ε4⁺ carriers, frontotemporal dementia, Parkinson's disease dementia, and vascular dementia. Univariable MR assessed causality, primarily via inverse variance weighting (IVW). Mediation effects were evaluated using the coefficient product method. Sensitivity analyses ensured robustness.</p><p><strong>Results: </strong>IVW-MR indicated statin medication significantly reduced AD risk but increased ADD and DLB risk. Elevated total cholesterol (TC) increased dementia, ADD, and DLB, while higher low density lipoprotein cholesterol decreased AD risk. Specific <i>DHCR24</i> variants reduced DLB risk, while <i>HMGCS1</i> variants increased it. <i>RAC1</i> variants lowered AD risk, whereas <i>RHOC</i> mitigated ADD risk. Critically, TC mediated 93.91% (95% CI = 68.27%∼119.55%) of statins' effect on dementia, 84.37% (95% CI = 62.21%∼106.52%) on ADD, and 61.94% (95% CI = 43.47%∼80.42%) on DLB. The genetically mimicked effect of statins does not show a mediating role.</p><p><strong>Conclusions: </strong>Statin medication, plasma lipids, and their genetic proxies exhibit causal links to cognitive impairment. Crucially, TC mediates statin-associated risks for cognitive impairment.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261440863"},"PeriodicalIF":2.8,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring potential genetic correlation and causality between cathepsins and neurodegenerative diseases: Insight from Mendelian randomization analyses.","authors":"Hui Shu, Rongmao He, Ziting Zhu, Wenlong Zhang, Pingyi Xu","doi":"10.1177/25424823261437791","DOIUrl":"https://doi.org/10.1177/25424823261437791","url":null,"abstract":"<p><strong>Background: </strong>Previous research has exhibited a potential association between cathepsins and neurodegenerative diseases (NDDs). Nevertheless, the causal relationships between cathepsins and different types of NDDs remain inadequately clear.</p><p><strong>Objective: </strong>We aim to explore the genetically correlation and causality between 4 NDDs and 9 cathepsins based on genome-wide association study platform.</p><p><strong>Methods: </strong>Cathepsin B, E, F, G, H, L2, O, S, and Z and four NDDs types, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and dementia with Lewy bodies, were obtained from large-scale genome-wide summary data. To explore potential interactive roles of these cathepsins in the pathogenesis of NDDs, we applied two-sample bidirectional univariable Mendelian randomization (MR) and multivariable MR, with inverse variance weighting as the primary statistical approach.</p><p><strong>Results: </strong>The univariable MR analysis revealed one positive and two negative causal effects between genetic liability in nine cathepsins and four NDDs. Reverse univariable MR analysis identified one negative causal link. Furthermore, the multivariable MR analysis not only confirmed two significant associations observed in the univariable analysis but also revealed a new positive effect.</p><p><strong>Conclusions: </strong>Our findings demonstrate that several cathepsins are causally associated with different NDDs, offering new insights into the underlying mechanisms of neurodegeneration. These results may contribute to the development of novel diagnostic and therapeutic strategies for managing neurodegeneration.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261437791"},"PeriodicalIF":2.8,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives on plasma biomarkers for point-of-care diagnostics in Alzheimer's disease: Insights into 2D-BioPAD.","authors":"Angeliki Koukoura, Kyriaki Antonopoulou, Apostolos C Tsolakis, Alina Solomon, Magda Tsolaki, Lutz Froelich, Anthoula Tsolaki, Eirini Papadaki, Efstathios Vassiliadis, Gitte Juel Holst","doi":"10.1177/25424823261437790","DOIUrl":"https://doi.org/10.1177/25424823261437790","url":null,"abstract":"<p><p>We investigated the potential of plasma biomarkers for point-of-care in vitro diagnostics in Alzheimer's disease by collecting insights from 99 stakeholders primarily from Greece, including patients, caregivers, healthcare professionals, and researchers. Data from an online survey was analyzed using descriptive statistics and thematic analysis. Key biomarkers reported by participants included Aβ₄₀, Aβ₄₂, pTau181, pTau217, and neurofilament light chain. While biomarkers were recognized for their value in prognosis, diagnosis, and monitoring, most participants were unfamiliar with point-of-care in vitro diagnostics. Major concerns regarding implementation included cost, reimbursement, and accessibility, underscoring the need for more feasible and context-appropriate diagnostic solutions.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261437790"},"PeriodicalIF":2.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring shared molecular pathways and gene signatures in type 2 diabetes mellitus and Alzheimer's disease in a Pakistani cohort.","authors":"Zarish Noreen, Tanmoy Mondal, Jheannelle Johnson, Jasneet Sahota, Christopher A Loffredo, Gail Nunlee-Bland, Brent Korba, Attya Bhatti, Vijay Chandra, Somiranjan Ghosh","doi":"10.1177/25424823251403462","DOIUrl":"10.1177/25424823251403462","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) a growing concern in low- and middle-income countries, including Pakistan. The relationship between T2DM and AD is complex and concerning, as more older adults with T2DM are experiencing cognitive impairment.</p><p><strong>Objective: </strong>The study aimed to investigate the relationship between T2DM and AD in a Pakistani population. Through transcriptomic analysis, this research explored shared molecular mechanisms, genes, and pathways between T2DM and AD.</p><p><strong>Methods: </strong>Our main cohort includes 820 participants, including individuals with T2DM, AD, T2DM + AD, and controls, from regional hospitals. Gene expression profiling and Ingenuity Pathway Analysis (IPA) were implemented in a subgroup of 18 participants to identify overlapping gene networks and canonical pathways implicated in both diseases. A TLDA array was used to identify genes associated with Amyloid processing and selected pathways.</p><p><strong>Results: </strong>Our findings indicate a significant (<i>p</i>-value 0.05) overlap in 58 dysregulated genes linked to neuroinflammation, mitochondrial dysfunction, and amyloid processing, suggesting shared pathogenic mechanisms in T2DM and AD. Notable genes, such as <i>CXCL5</i> and <i>APP</i>, were differentially expressed in both conditions, highlighting inflammation's role in neurodegeneration. <i>CAPNS2</i> and <i>CAPN1</i> showed the maximum relative expression differences in the TLDA array, providing potential targets for further investigation.</p><p><strong>Conclusions: </strong>The study provides insights into the complex interplay between T2DM and AD, revealing common molecular pathways, including neuroinflammation and mitochondrial dysfunction. Despite the small sample size, our findings underscore the importance of exploring these shared mechanisms, as they could play a potential role in future studies to identify early biomarkers.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823251403462"},"PeriodicalIF":2.8,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P-tau217 and %p-tau217 exhibited superior diagnostic accuracy over other blood biomarkers in the initial assessment of individuals being diagnosed with mild cognitive impairment and Alzheimer's disease dementia.","authors":"Qiongqiong Qiu, Weiqiang Qian, Wanying Zhao, Huanxin Xie, Lei Cao, Linlin Ye","doi":"10.1177/25424823261439687","DOIUrl":"10.1177/25424823261439687","url":null,"abstract":"<p><strong>Background: </strong>High-performance blood tests may improve diagnostic accuracy and support personalized treatment for Alzheimer's disease (AD), but validation at the time of initial clinical diagnosis remains limited.</p><p><strong>Objective: </strong>To assess whether plasma biomarkers can aid diagnostic decision-making at first clinical assessment, particularly as tools to triage patients for confirmatory testing in routine practice.</p><p><strong>Methods: </strong>We analyzed 241 cognitively normal (CN) controls, 211 patients with mild cognitive impairment (MCI), and 59 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. Plasma aliquots underwent analysis with the C2N Diagnostics PrecivityAD2^® and Roche Diagnostics Elecsys^® assays.</p><p><strong>Results: </strong>The AD group showed a lower Aβ₄₂/Aβ₄₀ ratio than the CN group (p < 0.01) and a mild decrease compared to the MCI group (p < 0.05). The AD group had significant increases in p-tau181, p-tau217, and %p-tau217 (p < 0.001) versus both MCI and CN groups. Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were also significantly elevated in AD. The MCI and CN groups only differed in p-tau217 and %p-tau217 (p < 0.05). The AD versus CN AUCs for p-tau181, p-tau217, and %p-tau217 were 0.84, 0.87, and 0.87; for AD versus MCI, they were 0.79, 0.80, and 0.81. The p-tau181, p-tau217, and %p-tau217 showed a moderate correlation with the Alzheimer's Disease Assessment Scale-cognitive subscale. %p-tau217 demonstrated a strong correlation with the p-tau181/Aβ₄₂ ratio in CSF (R = 0.72, p < 0.001).</p><p><strong>Conclusions: </strong>In the setting of first-presentation diagnosis of clinically defined MCI and AD, p-tau217, and %p-tau217 outperformed other plasma biomarkers and may help triage patients for further confirmatory evaluation.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261439687"},"PeriodicalIF":2.8,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of publicly available digital dementia risk screening tools: A scoping review.","authors":"Zandile Rwodzi, Maddison L Mellow, Dan Ping Wu, Kate Laver, Dorothea Dumuid, Ashleigh E Smith","doi":"10.1177/25424823261433534","DOIUrl":"10.1177/25424823261433534","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease and related dementias have long prodromal phases during which addressing modifiable lifestyle factors may help delay onset. Digital dementia risk screening tools are emerging as an accessible method to convey risk information and promote preventive strategies. However, little is known about the characteristics, intended users, and risk factor coverage of these tools.</p><p><strong>Objective: </strong>To identify and summarize publicly available digital dementia risk screening tools, including their components (risk factors), administration methods, target populations, and implementation settings.</p><p><strong>Methods: </strong>A two-phase systematic search was conducted. Phase 1 involved searching Embase, MEDLINE (Ovid), APA PsycINFO, and Google Scholar for digital dementia screening tools. To be included in this review, tools needed to be publicly available, focused on dementia, containing at least one modifiable risk factor, targeted at adults, and published in English. Phase 2 examined the psychometric properties of the identified tools (when administered to older adults).</p><p><strong>Results: </strong>Eleven tools met inclusion criteria: CogDrisk, ANU-ADRI, BDSI, DemPort, UKBDRS, CAIDE, LIBRA, Alzhe Alert, DRA, UKB-DRP, and the Knight Alzheimer's Disease Risk Calculator. Tools were web- or app-based and designed for use by individuals, clinicians, or researchers. While the most recent Lancet Commission outlines 14 modifiable risk factors, only 11 were covered across these tools. Only one tool had reported psychometric properties.</p><p><strong>Conclusions: </strong>Several digital tools for dementia risk screening are publicly available, but most remain in early development and require further validation in real-world adult populations. Future research should evaluate their reliability and effectiveness to support early identification and behavior change.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261433534"},"PeriodicalIF":2.8,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into the role of extracellular-to-total body water ratio on neurocognitive decrements over time in Asians with type 2 diabetes.","authors":"Serena Low, Angela Moh, Huili Zheng, Theedaraj Bun Chuan, Keven Ang, Wern Ee Tang, Ziliang Lim, Tavintharan Subramaniam, Chee Fang Sum, Su Chi Lim","doi":"10.1177/25424823261421570","DOIUrl":"10.1177/25424823261421570","url":null,"abstract":"<p><strong>Background: </strong>Extracellular water-to-total body water (ECW/TBW) ratio reflects volume overload. It promotes aortic stiffness which predicts Alzheimer's disease and related dementias (ADRD) development.</p><p><strong>Objective: </strong>We studied longitudinal relationship between ECW/TBW ratio and neurocognitive decrements in type 2 diabetes (T2D) and mediating role of aortic stiffness.</p><p><strong>Methods: </strong>In a prospective Asian cohort, we measured ECW/TBW ratio using bioimpedance analysis (BIA) and pulse wave velocity (PWV) using applanation method. The Repeatable Battery for Assessment of Neuropsychological Status (RBANS) was used to assess neurocognitive performance. Linear mixed model was applied to examine if ECW/TBW was associated with neurocognitive performance.</p><p><strong>Results: </strong>The study comprised 1412 patients at baseline. Over maximum of 9.4 years' follow-up, 823 patients had repeated neurocognitive assessment. We observed associations between higher ECW/TBW ratio (continuous variable) and edema group with lower total RBANS score. The adjusted coefficients were -1.43 (95%CI -2.31, -0.56) and -5.88 (95%CI -9.00, -2.75) respectively. There were similar observations for delayed memory, visuospatial/constructional and attention. Based on cross-lagged panel model, there was larger standardized effect size from baseline ECW/TBW ratio to follow-up total RBANS score (β = 0.053, p = 0.026) compared to that from baseline total RBANS score to follow-up ECW/TBW ratio (β = -0.020, p = 0.461). PWV mediated 13.3% of the relationship.</p><p><strong>Conclusions: </strong>Our results demonstrated a relationship between volume overload and cognitive decrements, with potential mediation from aortic stiffness. There was temporal precedence of ECW/TBW over neurocognitive performance. BIA-determined ECW/TBW ratio is a promising biomarker of neurocognitive decrements in T2D.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261421570"},"PeriodicalIF":2.8,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidimensional burden of caregivers of Alzheimer's disease and related dementia in China: A nationwide cross-sectional study.","authors":"Dangui Zhang, Yongleng Fang, Minglong Huang, Meiyu Wang, Weijin Li, Yuhan Gong, William Ba-Thein","doi":"10.1177/25424823261433567","DOIUrl":"10.1177/25424823261433567","url":null,"abstract":"<p><strong>Background: </strong>As China's population ages, the burden on caregivers of individuals with Alzheimer's disease and related dementias (ADRD) is increasing. Comprehensive nationwide studies on caregiver burden, particularly emotional experiences, however, remain limited.</p><p><strong>Objective: </strong>To investigate the multidimensional aspects of caregiving burden associated with ADRD patients through a nationwide survey.</p><p><strong>Methods: </strong>This cross-sectional study included 1221 ADRD patient-caregiver pairs from 29 province-level administrative divisions in mainland China, recruited through dementia-dedicated online forums. The multidimensional aspect of caregiver burden, including physical, mental, familial, emotional, and quality-of-life impact, as well as attitudes toward caregiving and needed supports, was measured using a self-reported assessment.</p><p><strong>Results: </strong>Patients had a median age of 66 years, with 33% classified as young-onset dementia (YOD). Caregivers were predominantly younger (median age: 30), employed (96.6%), and male (59.8%). Most reported moderate-to-severe physical (24.2%), mental (31.0%), family life (29.2%), and quality-of-life (47.2%) burden, with high emotional strain (ambivalence: 66.7%; grief: 59.8%; guilt: 57.7%). Independent predictors of burden included patient mood, caregiver emotional states, and caregiving extent, while financial stability and positive caregiving attitudes were identified as protective factors. Caregivers prioritized financial aid (25.1%), additional helpers (19.7%), and psychological support (16.7%).</p><p><strong>Conclusions: </strong>This nationwide study highlights the multidimensional burden faced by ADRD caregivers in China. Predominantly younger, employed, and male caregivers reflect shifting sociocultural dynamics. The high prevalence of YOD adds complexity to caregiving demands. Our findings underscore the need for evidence-based individualized support mechanisms, such as psychosocial and workplace interventions, to alleviate caregiver burden in China.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261433567"},"PeriodicalIF":2.8,"publicationDate":"2026-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct brain volume changes associated with the head-turning sign and Neucop-Q response patterns in Alzheimer's disease.","authors":"Memi Watanabe, Shogyoku Bun, Atsushi Shimizu, Yu Iwabuchi, Susumu Mori, Masahiro Jinzaki, Masaru Mimura, Daisuke Ito","doi":"10.1177/25424823261437682","DOIUrl":"10.1177/25424823261437682","url":null,"abstract":"<p><strong>Background: </strong>The \"head-turning sign\" (HTS) and Neurocognitive Questionnaire (Neucop-Q) capture <i>toritsukuroi</i> (saving appearance) behaviors commonly observed in Alzheimer's disease (AD). Neucop-Q is a brief screening questionnaire assessing current event memory (News; N), self-awareness/concern (Consciousness; C), and engagement in pleasurable activities (Pleasure; P). Previously, HTS-positivity and impaired N/impaired C/normal P (NimpCimpPnor) combination show high specificity for amyloid PET positivity.</p><p><strong>Objective: </strong>To investigate the neuroanatomical correlates of HTS and specific Neucop-Q response patterns across the AD continuum.</p><p><strong>Methods: </strong>One hundred thirty-seven individuals (54 cognitively normal controls, 9 preclinical AD, 36 mild cognitive impairment, and 38 AD dementia patients) underwent clinical evaluation and structural MRI. Gray matter volumes were analyzed using voxel-based morphometry with MVision software based on a Multi-Atlas Likelihood Fusion approach. Regional volumes were normalized to intracranial volume and adjusted for age and sex. Group differences were tested with false discovery rate (FDR) correction, and logistic regression assessed associations between regional volume and Neucop-Q responses.</p><p><strong>Results: </strong>HTS was significantly associated with right hippocampal atrophy (FDR-corrected p = 0.024). In the logistic regression analyses, none of the associations survived correction for multiple comparisons. The NimpCimpPnor combination was correlated with medial and inferior temporal lobe atrophy (FDR < 0.01) and larger globus pallidus (FDR = 0.034), with logistic regression surviving correction.</p><p><strong>Conclusions: </strong>HTS reflected reduced right hippocampal volume, whereas NimpCimpPnor involved broader temporal atrophy with relatively larger pallidal volumes, suggesting distinct regional gray matter patterns across behavioral response profiles.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"10 ","pages":"25424823261437682"},"PeriodicalIF":2.8,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13039071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147610525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}